FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2889799503> ?p ?o ?g. }

• W2889799503 abstract "e15658 Background: HCC is associated with a worse prognosis in pts with high baseline AFP levels. The relationship between elevated baseline AFP and survival benefit with systemic HCC treatments in the real world setting is poorly characterized. Methods: A retrospective analysis of clinical outcomes among newly diagnosed advanced HCC pts treated in US community-based oncology practice settings was conducted. Pts treated with sorafenib or best-supportive care (BSC) between 10/1/2007 and 12/31/2013 were identified in the International Oncology Network electronic medical record (EMR) database and were followed until date of death, date of last visit, or 06/30/2014 (end of study). Baseline demographics, clinical characteristics, and AFP (≤ or > 400 ng/mL), plus date of death were extracted from the EMR and physician progress notes. Treatment differences in OS were evaluated and stratified by AFP, AST/ALT, and bilirubin using unadjusted Cox proportional hazards regression models. Results: A total of 370 advanced HCC pts receiving sorafenib (217) or BSC (153) were identified. The mean age was 65.6 years and 77.0% were male. Cirrhosis (38.4%), hepatitis C (36.8%), and alcoholic liver disease (22.4%) were common hepatic-related comorbidities. 45.1% of pts had elevated AFP ( > 400 ng/mL) at baseline. The sorafenib cohort had significantly longer median OS time than the BSC cohort (29.6 vs 19.7 weeks, p= 0.048). OS for sorafenib vs BSC cohorts with AFP≤400 ng/mL and AFP > 400 ng/mL were 45.1 vs 25.3 weeks ( p= 0.128) and 25.3 vs 13.1 weeks ( p =0.197), respectively. Cox models revealed a consistent effect of sorafenib vs. BSC, regardless of AFP level (AFP ≤400ng/mL: HR = 0.79 (95% CI 0.55-1.13), p= 0.200; AFP > 400 ng/mL: HR = 0.80 (95% CI 0.53-1.52), p= 0.297). Conclusions: This study supports the poor prognosis for advanced HCC pts with baseline AFP levels > 400 ng/mL compared to baseline AFP ≤400 ng/mL. Limitations with retrospective, real-world studies require caution in interpretation, but this analysis suggests an OS benefit with sorafenib treatment compared to BSC. There remains an unmet need for effective therapies for advanced HCC associated with elevated AFP levels." @default.
• W2889799503 created "2018-09-27" @default.
• W2889799503 creator A5007968325 @default.
• W2889799503 creator A5013810224 @default.
• W2889799503 creator A5020930636 @default.
• W2889799503 creator A5026201262 @default.
• W2889799503 creator A5040067170 @default.
• W2889799503 creator A5043605449 @default.
• W2889799503 creator A5049458198 @default.
• W2889799503 creator A5053765111 @default.
• W2889799503 creator A5060428080 @default.
• W2889799503 creator A5073651333 @default.
• W2889799503 date "2017-05-20" @default.
• W2889799503 modified "2023-09-22" @default.
• W2889799503 title "Overall survival (OS) in patients (pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): A real-world retrospective study." @default.
• W2889799503 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e15658" @default.
• W2889799503 hasPublicationYear "2017" @default.
• W2889799503 type Work @default.
• W2889799503 sameAs 2889799503 @default.
• W2889799503 citedByCount "0" @default.
• W2889799503 crossrefType "journal-article" @default.
• W2889799503 hasAuthorship W2889799503A5007968325 @default.
• W2889799503 hasAuthorship W2889799503A5013810224 @default.
• W2889799503 hasAuthorship W2889799503A5020930636 @default.
• W2889799503 hasAuthorship W2889799503A5026201262 @default.
• W2889799503 hasAuthorship W2889799503A5040067170 @default.
• W2889799503 hasAuthorship W2889799503A5043605449 @default.
• W2889799503 hasAuthorship W2889799503A5049458198 @default.
• W2889799503 hasAuthorship W2889799503A5053765111 @default.
• W2889799503 hasAuthorship W2889799503A5060428080 @default.
• W2889799503 hasAuthorship W2889799503A5073651333 @default.
• W2889799503 hasConcept C126322002 @default.
• W2889799503 hasConcept C143998085 @default.
• W2889799503 hasConcept C167135981 @default.
• W2889799503 hasConcept C2778019345 @default.
• W2889799503 hasConcept C2780624289 @default.
• W2889799503 hasConcept C3019894029 @default.
• W2889799503 hasConcept C71924100 @default.
• W2889799503 hasConcept C90924648 @default.
• W2889799503 hasConceptScore W2889799503C126322002 @default.
• W2889799503 hasConceptScore W2889799503C143998085 @default.
• W2889799503 hasConceptScore W2889799503C167135981 @default.
• W2889799503 hasConceptScore W2889799503C2778019345 @default.
• W2889799503 hasConceptScore W2889799503C2780624289 @default.
• W2889799503 hasConceptScore W2889799503C3019894029 @default.
• W2889799503 hasConceptScore W2889799503C71924100 @default.
• W2889799503 hasConceptScore W2889799503C90924648 @default.
• W2889799503 hasLocation W28897995031 @default.
• W2889799503 hasOpenAccess W2889799503 @default.
• W2889799503 hasPrimaryLocation W28897995031 @default.
• W2889799503 hasRelatedWork W1988508343 @default.
• W2889799503 hasRelatedWork W2057869441 @default.
• W2889799503 hasRelatedWork W2095577289 @default.
• W2889799503 hasRelatedWork W2244845765 @default.
• W2889799503 hasRelatedWork W2269709568 @default.
• W2889799503 hasRelatedWork W2283819779 @default.
• W2889799503 hasRelatedWork W2526454245 @default.
• W2889799503 hasRelatedWork W2760934854 @default.
• W2889799503 hasRelatedWork W2772954994 @default.
• W2889799503 hasRelatedWork W2807836411 @default.
• W2889799503 hasRelatedWork W2908457113 @default.
• W2889799503 hasRelatedWork W2911868143 @default.
• W2889799503 hasRelatedWork W2993032707 @default.
• W2889799503 hasRelatedWork W3032848736 @default.
• W2889799503 hasRelatedWork W3081041387 @default.
• W2889799503 hasRelatedWork W3111506543 @default.
• W2889799503 hasRelatedWork W3127035384 @default.
• W2889799503 hasRelatedWork W3174418075 @default.
• W2889799503 hasRelatedWork W3196054987 @default.
• W2889799503 hasRelatedWork W4220727949 @default.
• W2889799503 isParatext "false" @default.
• W2889799503 isRetracted "false" @default.
• W2889799503 magId "2889799503" @default.
• W2889799503 workType "article" @default.